Sara Rezzola

TL;DR: Analysis of vitreous humor obtained from diabetic patients has made it possible to identify some of the mediators responsible for DR pathogenesis, and the main Vitreous-related factors triggering the occurrence of retinal complication in diabetes are highlighted.

TL;DR: Anti-inflammatory compounds such as intravitreal glucocorticoids, topical non-steroidal anti-inflammatory drugs (NSAIDs), antioxidants, inflammatory molecule inhibitors, renin-angiotensin system (RAS) blockers and natural anti- inflammatory therapies may all be considered to reduce the rate of administration of antineovascularization agents in the treatment of DR.

TL;DR: Using pharmacophore modeling of the interaction of a minimal PTX3-derived FGF-binding pentapeptide with FGF2, a small-molecule chemical (NSC12) that acts as an extracellular FGF trap with significant implications in cancer therapy is identified.

TL;DR: How studying the biological activity of the vitreous in different in vitro, ex vivo, and in vivo experimental models can provide insights into the pathogenesis of diabetic retinopathy is discussed.

TL;DR: In vitro and ex vivo angiogenesis assays may be suitable for a rapid screening of potential anti-angiogenic molecules before in vivo validation of the putative lead compounds, and recent observations have shown that eye neovascularization in zebrafish embryos, an in vivo animal platform experimentally analogous to in vitro/ex vivo models, may represent a novel target for the identification of angiogenic inhibitors.